

RESEARCH PEPTIDE

RETATRUTIDE

GLP-1 + GIP + GLUCAGON

Metabolic Health & Weight Management Research



RESEARCH
TODAY



DISCOVER
TOMORROW



A HEALTHIER
HUMAN POTENTIAL



SCIENCE
INSPIRES
HUMAN
POTENTIAL



WHAT IS RETATRUTIDE AND WHY IS IT STUDIED?

Retatrutide is an investigational triple-receptor agonist studied in metabolic-health and weight-management research. It targets GLP-1, GIP and glucagon pathways involved in appetite, glucose handling, insulin sensitivity and energy expenditure. Research interest includes body composition, metabolic markers and cardiometabolic-risk models.



AT A GLANCE



30 mg vial



Research focus:
weight management, metabolic health,
insulin sensitivity, glucose control



Format: lyophilized powder



WHAT IT IS STUDIED FOR

- Obesity and weight-management research
- Metabolic-syndrome models
- Type 2 diabetes research
- Insulin-resistance research
- Body-composition research
- Cardiometabolic-risk studies



HOW IT MAY WORK

- GLP-1 activity is studied for appetite regulation and satiety
- GIP activity is studied for insulin sensitivity and glucose control
- Glucagon activity is studied for energy expenditure and fat oxidation
- Triple agonist targets complementary metabolic pathways



WHAT RESEARCHERS MAY LOOK FOR OVER TIME

WEEKS 1-4

Appetite reduction and earlier satiety may begin.

WEEKS 5-8

Continued appetite control and glucose regulation may be evaluated.

WEEKS 9-16

Body-composition and metabolic-marker changes may become clearer.

16+ WEEKS

Continued weight and metabolic outcomes may be assessed.



30 MG RESEARCH PROTOCOL

Reconstitution	3 mL bacteriostatic water
Final concentration	30 mg / 3 mL = 10 mg/mL
Starting dose	1 mg once weekly
Syringe reference	10 units = 1 mg
Frequency	Once weekly
Research duration	24-48+ weeks
Administration	Subcutaneous injection
Storage	Refrigerate after reconstitution
Titration	Increase by 1 mg every 4 weeks



MIXING

30 mg + 3 mL BAC water = 10 mg/mL

10 units = 1 mg



TITRATION

Start at 1 mg once weekly. Increase by 1 mg every 4 weeks according to the research protocol and tolerability criteria.



IMPORTANT CONSIDERATIONS

- For educational and research purposes only
- Limited human research data
- Avoid use in active or recent cancer research subjects
- Not recommended during pregnancy or breastfeeding
- Store appropriately after reconstitution



EVIDENCE LEVEL

- Human research – Emerging
- Animal research – Extensive
- Mechanistic evidence – Strong
- Long-term safety data – Limited



RESEARCH USE DISCLAIMER

For educational and research use only. Not for human use. Not approved by the FDA or any other regulatory authority. Research compounds are not intended for diagnosis, treatment, or prevention of any disease.